Orexo Logo

Orexo

Develops pharmaceuticals and digital therapies for substance use and mental health.

ORX | ST

Overview

Corporate Details

ISIN(s):
SE0000736415 (+2 more)
LEI:
549300LJ5CCWDPTK9Z08
Country:
Sweden
Address:
Box 303, 751 05 UPPSALA

Description

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-03-10 11:00
Kallelse till årsstämma i Orexo
Swedish 233.9 KB
2021-02-05 16:30
Orexo påkallar förtida inlösen av utestående obligationer och erhåller temporär…
Swedish 541.3 KB
2021-02-05 16:30
Orexo calls for redemption of its outstanding bonds and obtains temporary waiver
English 548.1 KB
2021-02-04 18:00
Orexo har framgångsrikt emitterat seniora icke-säkerställda obligationer
Swedish 682.8 KB
2021-02-04 18:00
Orexo has successfully issued senior unsecured callable floating rate bonds
English 682.5 KB
2021-02-01 08:00
Orexo överväger emittera seniora icke-säkerställda obligationer
Swedish 540.0 KB
2021-02-01 08:00
Orexo contemplates issue of senior unsecured callable floating rate bonds
English 446.4 KB
2021-01-28 08:00 Swedish 1019.4 KB
2021-01-28 08:00 English 1.0 MB
2020-11-04 11:10
Correction notice of press release – Q3 2020 Interim Report – ZUBSOLV® guiding …
English 440.0 KB
2020-11-04 11:10
Rättelse av pressmeddelande – delårsrapport – ZUBSOLV® guidning 2020
Swedish 533.1 KB
2020-11-04 08:00 Swedish 987.3 KB
2020-11-04 08:00 English 969.9 KB
2020-09-28 13:41 English 36.0 KB
2020-08-10 08:00
Orexo har mottagit ett paragraf IV-meddelande för ZUBSOLV® i USA
Swedish 578.4 KB

Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orexo

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orexo via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-11 Nikolaj Arrild Sørensen Other Buy 2,460 35,178.00 SEK
2025-04-04 Nikolaj Arrild Sørensen Other Buy 3,500 47,530.00 SEK
2024-03-26 Fredrik Järrsten Other Buy 3,000 44,040.00 SEK
2023-11-24 Charlotte Vithlani Hansson Other Buy 3,000 44,640.00 SEK
2023-11-08 Fredrik Järrsten Other Buy 1,500 23,715.00 SEK
2023-02-24 Nikolaj Arrild Sørensen Other Buy 11,500 188,945.00 SEK
2023-01-27 Fredrik Järrsten Other Buy 4,500 79,695.00 SEK
2022-07-26 Michael Matly Other Buy 2,820 60,777.77 SEK
2022-07-21 Charlotte Vithlani Hansson Other Buy 3,000 61,500.00 SEK
2022-07-15 James Noble Other Buy 18,500 394,252.80 SEK

Peer Companies

Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM
Carna Biosciences, Inc. Logo
Clinical-stage biopharma developing small molecule kinase inhibitors.
Japan
4572
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America
CASI
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America
CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America
YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America
CDT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.